A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma

CONCLUSIONS: Our study introduced a prognostic model based on DRGs, which could forecast the prognosis of patients with LUAD. The biomarker ACTN4 exhibits promise for the diagnosis and management of LUAD, given its correlation with tumor immune infiltration and m6A modification.PMID:38517776 | DOI:10.3233/CBM-230276

Source: Cancer Biomarkers - March 22, 2024 Category: Cancer & Oncology Authors: Kai Xie Bin Wang Pei Pang Guangbin Li Qianqian Yang Chen Fang Wei Jiang Yu Feng Haitao Ma Source Type: research